Previous Meeting EHDN2020
When: September 11, 2020 Time: 14:00 – 18:15 CET
(uploaded November 10, 2020)
| Recorded sessions: |
— |
|
| Welcome and introduction
Anne Rosser
Astri Arnesen
Patrick Weydt |
|
|
Scientific progress session
- Chair: Lesley Jones
- Function of HTT – Frédéric Saudou
- Somatic expansion of the HTT CAG repeat – Darren Monckton
- HTT phosphorylation and TBK1 – Hilal Lashuel
- Oral HTT-lowering therapy – George McAllister
- Q&A and Discussion
|
|
|
Clinical studies session – PART 1
- Chair: Jean-Marc Burgunder
- An Update from the Tominersen Global Clinical Development Programme – Sarah Tabrizi
- PRECISION HD1 and 2: allele selective targeting of the mutant HTT – Anna Heinzmann
- Shield-HD – Anne Rosser
- Prilenia – Bernhard Landwehrmeyer
- First Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest HD – Ralf Reilmann
|
|
|
Clinical studies session – PART 2
- Chair: Jean-Marc Burgunder
- MIG-HD trial – Anne-Catherine Bachoud-Levi
- HEATED- Huntington’s Equal Access to Effective Drugs – Hugh Rickards
- Q&A and Discussion
|
|
|
| Closing remarks
Bernhard Landwehrmeyer
Anne Rosser |
|
|
